SCHEMBL5755594

SCHEMBL5755594

CSCC[C@@H](NS(=O)(=O)c1ccc2nc(SCC3CCCCC3)sc2c1)C(=O)NO

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
TSHR P16473 2/20 0.48
HSP90AA1 P07900 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41
RAB9A P51151 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 2/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CLK1 P49759 1/20 0.38
BMP1 P13497 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756059 0.92 RXFP1 (0.50) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5755212 0.87 ALDH1A1 (0.51) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5755993 0.85 MMP2 (0.48) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5756642 0.85 SMN1; SMN2 (0.50) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5756877 0.83 MEN1 (0.45) LMNAL3MBTL1MEN1CYP2C9KMT2A
SCHEMBL5753295 0.83 PPARA (0.45) L3MBTL1MEN1CYP2C9KMT2ARXFP1
SCHEMBL5757798 0.81 LMNA (0.52) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5755972 0.80 POLB (0.48) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL5757831 0.80 SMN1; SMN2 (0.51) ALDH1A1LMNAHTTTSHRHSP90AA1
SCHEMBL6975596 0.77 SMN1; SMN2 (0.47) ALDH1A1LMNAHTTTSHRHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885LMNA 1839/4885HTT 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.